Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–62 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Next Generation Sequencing (NGS) Clear all

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more

Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions: Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P); Diagnostic Test · Drug · Other
Lead sponsor: Taproot Health; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Laredo, Texas

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions: A2B530, xT-Onco with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Colorectal Cancer
Interventions: Guardant SHIELD blood-based colorectal cancer screening test; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Down Syndrome, Trisomy 18, Trisomy 13
Interventions: SmartNIPT; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Bridgeport, Connecticut + 9 more

Conditions: Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions: blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA]); Procedure
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more

Conditions: Large-Cell Neuroendocrine Carcinoma
Interventions: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma, Treatment for Small Cell Lung Cancer; Other
Lead sponsor: Charles Kunos; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions: Not listed
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more

Conditions: Kidney Transplant Rejection
Interventions: AlloSure; Device
Lead sponsor: CareDx; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Fairfield, California • Fresno, California • Granada Hills, California + 15 more

Conditions: Infertility, Aneuploidy
Interventions: Preimplantation Genetic Screening by NGS; Other
Lead sponsor: Illumina, Inc.; Industry
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Tempe, Arizona • Encino, California • Laguna Niguel, California + 24 more

Conditions: Cytopenia
Interventions: Identification of specific markers; Other
Lead sponsor: Meyer Children's Hospital IRCCS; Other
Eligibility: 1 Year to 17 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Muscle-Invasive Bladder Carcinoma
Interventions: C2i Test; Diagnostic Test
Lead sponsor: C2i Genomics; Industry
Eligibility: 22 Years to 100 Years
Enrollment: 3 participants
Timeline: 2022
U.S. locations: 1
States / cities: Bloomfield, New Jersey

Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg; Drug · Biological · Dietary Supplement
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more

Search by objective public record fields.

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

The Registry of Oncology Outcomes Associated With Testing and Treatment

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Understanding Patient Preference on Colorectal Cancer Screening Options

VAlidation of a Lower Cost aneUploidy scrEen

A Screening Study Targeting Tumor-specific Antigens

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Transition of Renal Patients Using AlloSure Into Community Kidney Care

Single Embryo TrAnsfeR of Euploid Embryo

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Clinical Performance Evaluation of the C2i-Test

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC